Boston Scientific Outlines Growth And Expansion Strategy - Quick Facts

(RTTNews) - Boston Scientific Corporation (BSX) announced the company is targeting at- or above-market operational revenue growth, and consistent double-digit adjusted EPS growth (excluding the negative impact of foreign currency) through ongoing operating margin improvement initiatives, and a differentiated five-year growth strategy aims for 25 percent adjusted operating margins by 2017.

The company said it continues to increase penetration into emerging markets, which represented 10 percent of sales in 2014 on a reported basis, up from 8 percent in 2013. The company plans to move emerging market mix to 15 percent of sales in 2017 on a constant currency basis.

The company said a strategic alliance with Frankenman Medical Equipment is expected to support continued growth, development and manufacturing capabilities in China, and further expand the company's global footprint.

"We continue to broaden our geographic reach and diversify our portfolio into markets with compelling growth opportunities. We are entering segments within each of our markets that are projected to grow faster than the overall market over the next five years, and we expect to continue to diversify our portfolio away from 60 percent in slower growth markets in 2012 to 40 percent by 2019," said Dan Brennan, executive vice president and chief financial officer.